FDA faces congressional scrutiny over baby formula shortage

- Advertisement -


The head of the Food and Drug Administration is facing congressional lawmakers for the first time over the national shortage of baby formula

- Advertisement -

- Advertisement -

FDA Commissioner Robert Califf’s appearance before a House subcommittee comes just hours after Biden announced a stepped-up response to the issue: invoking the Defense Production Act to speed domestic manufacturing and authorizing flights to import formula from overseas.

- Advertisement -

Califf is the first administration official to testify before Congress on the issue, which has left some parents hunting for formula and become a talking point for Republicans. Behind the shortage are several distinct issues, including supply disruptions caused by the coronavirus pandemic and the recent shutdown of the largest US formula factory.

Earlier this week, the FDA announced several steps to address the problem, including a preliminary agreement with formula maker Abbott Nutrition to reopen its plant, which has been shuttered since February due to contamination. The agency is also streamlining the process for international manufacturers to import more formula.

Members of a House Appropriations subcommittee have signaled that they will ask Califf why the FDA didn’t act sooner to help head off the supply challenges. Lawmakers have also suggested the FDA missed opportunities to catch the problems at Abbott’s plant as early as last fall.

Rep. Rosa DeLauro, D-Conn., recently released a whistleblower complaint alleging numerous safety violations at Abbott’s plant, including employees falsifying records and failing to properly test formula before releasing it. She said the former Abbott employee alerted the FDA to the situation in October but was not interviewed by agency staff until late December.

And there are other questions about the FDA’s timeline for dealing with Abbott. The company shut its Michigan plant in February after FDA inspectors began investigating four bacterial infections in infants who had consumed formula from the plant. The first of those cases was reported to the FDA in September though agency staff didn’t begin inspecting the facility until late January. Califf said earlier this week the agency’s investigation is ongoing and it hasn’t yet reached a conclusion on whether bacteria from the plant caused the infant infections.

Abbott says there is no direct evidence linking its products to the illnesses.

While the baby formula shortage is certain to take center stage, Thursday’s hearing was originally scheduled to review the FDA’s budget request for next year. Califf is expected to ask lawmakers for $76 million in new funding for food safety and nutrition, according to prepared remarks. The request comes amid longstanding concerns that the FDA’s food program — which oversees most US foods except meat, poultry and eggs — has been underfunded compared with the agency’s drug and medical divisions.

On Wednesday evening, House Democrats passed a $28 million spending bill that would boost FDA funding to inspect domestic and international formula producers. It’s fate in the Senate is uncertain.
buy albuterol online www.adentalcare.com/wp-content/themes/medicare/languages/en/albuterol.html no prescription

,

Follow Matthew Perrone on Twitter: @—FDAwriter.

,

The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The is solely responsible for all content.

,

Credit: abcnews.go.com /

- Advertisement -

Stay on top - Get the daily news in your inbox

DMCA / Correction Notice

Recent Articles

Related Stories

Stay on top - Get the daily news in your inbox